PCN7: FAMILY CAREGIVING COSTS FOR THE ELDERLY WITH CANCER: ESTIMATES FROM A REPRESENTATIVE SAMPLE OF THE UNITED STATES  by Langa, K et al.
352 Abstracts
not economically important. HFS very rarely lead to hospi-
talization (0.7%) and was generally effectively managed by
dose interruption or appropriate dose reduction and patient
education. CONCLUSION: Treatment with capecitabine
avoided 57 hospital days per 100 patients and reduced use
of high-cost medications for AEs by 56% compared to M-
regimen. Reduction in hospitalization observed in this trial
would result in savings in the range of €17,000–€29,000
(depending on country) per 100 patients. AE profiles of dif-
ferent regimens are likely to be important economic factors
in oncology. Stomatitis, infection/sepsis and neutropenia
are of particularly high economic relevance.
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OBJECTIVES: To assess whether different methods of
asking for the willingness to pay (WTP) lead to different
outcomes. METHODS: Sixty people from the general
population were asked for their WTP for a new drug re-
lieving breakthrough cancer pain by a trained interviewer.
All the individuals answered WTP questions posed in
three different randomized ways with the open-card method.
First, they gave their WTP as patients, under certainty of
needing the drug (use or consumption value of the good).
Second, they gave their WTP for a private insurance (op-
tion value) given a probability of 10% of needing the
drug one day. Last, they gave their WTP as contributors
by paying taxes (existence value). The hypothesis of the
research was that the role adopted by the respondent in
the hypothetical situation described for each method in-
fluences results. We expected the WTP for the drug with
the simple method (under certainty) to be lower than the
WTP with the private insurance method and the latter to
be lower than the WTP with the contributor method, as
the different values of the good should be cumulative.
RESULTS: The duration of the interview was between 20
and 25 minutes. Data analysis showed that the different
methods have an influence on the WTP for the drug and
that certain sociodemographic characteristics of the indi-
viduals have an impact on study results. The relevance of
the differences found will be discussed during the presen-
tation. CONCLUSIONS: Different methods of asking for
the WTP lead to differences in outcomes.
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OBJECTIVE: To compare the Quality of Life (QoL) in-
dexes of received two different schemes of chemotherapy
patients in advanced breast cancer. METHODS: Patients
were assigned to chemotherapy. Arm A: standard scheme
CAF (23 pts.), and arm B: included docetaxel scheme
TAD (23 pts.). The instrument for QoL assessment was
FACT-Taxane (Functional Assessment of Cancer Ther-
apy for patients with Taxane toxicity). The questionnaire
consists from 43 questions, 27 of them are general ques-
tions and 16 are questions concerning toxicity reactions
of patients. The patients should answer the questions of
the questionnaire before the treatment, after 3rd and 6th
cycles of chemotherapy. RESULTS: According to re-
ceived data toxicity reactions were more pointed for
TAD scheme than for CAF scheme. The mediana of util-
ity indexes was 57.6 and 51.0 respectively after the 6th
cycle for additional (specific for Taxane) questions. But
the general utility index for arm B was higher than for
arm A, 112 and 109 respectively. CONCLUSION: In
Russia the most limiting factors of docetaxel usage are
related to cost and toxicity issues. In this study we receive
reliable evidence that docetaxel toxicity doesn’t influence
general QoL of the patients. Also in spite of toxicity reac-
tions the QoL of docetaxel treated patients was higher
than standard scheme treated patients. 
PCN7
FAMILY CAREGIVING COSTS FOR THE ELDERLY 
WITH CANCER: ESTIMATES FROM A 
REPRESENTATIVE SAMPLE OF THE
UNITED STATES
Langa K1, Hayman J1, Kabeto M1, Chernew M1, Katz S1, Slavin 
M2, Fendrick AM1
1University of Michigan, Ann Arbor, MI, USA; 2Ortho Biotech, 
Raritan, NJ, USA
OBJECTIVE: As the US population ages, the increasing
prevalence of cancer is likely to result in higher direct
medical and non-medical costs. While estimates of can-
cer-related direct medical costs exist, very little informa-
tion is available regarding family caregiving costs for eld-
erly cancer patients. Our objective was to determine valid
and generalizable estimates of family caregiving costs for
elderly cancer patients in the US. METHODS: We used
data from the first wave (1993) of the Asset and Health
Dynamics (AHEAD) Study, a nationally representative
longitudinal survey of people aged 70 or older living in
the community. We used a multivariable two-part regres-
sion model to control for differences in health status, so-
cial support, and sociodemographics. The adjusted prob-
ability of receiving family care, the adjusted average
weekly number of caregiving hours, and the average an-
nual caregiving cost per case (assuming an average hourly
wage of $8.30) was estimated for these three groups. RE-
SULTS: Of the 7443 subjects surveyed, 6422 (86%) re-
ported no history of cancer (No Ca), 718 (10%) reported
having a diagnosis of cancer but not receiving treatment
for their cancer in the last year (Ca/No Tx) and 303 (4%)
reported receiving treatment for their cancer in the last
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year (Ca/Tx). The Ca/Tx group was more likely to re-
ceive family care (34% vs. 26% for the Ca/No Tx and
the No Ca groups, P.05), and received significantly
more weekly hours of care (10.2 hours vs. 6.6 for the Ca/
No Tx and 7.0 for the No Ca groups, P.05) The aver-
age absolute increase in weekly family caregiving hours
for the Ca/Tx group (3.2 hours) represents an annual
cost of over $1.1 billion in the US. CONCLUSION: Fam-
ily caregiving costs for the elderly with cancer are sub-
stantial and should be considered when estimating the
cost of cancer treatment in the elderly.
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OBJECTIVE: To perform a cost-utility analysis compar-
ing paclitaxel, docetaxel, mitomycine plus vinorelbine
and standard therapy considering clinical efficacy, qual-
ity-adjusted-life-years and costs. METHODS: A decision
model was constructed for this cost-utility analysis. Clin-
ical efficacy data were collected by literature review and
expert opinion. Two-phase III clinical trials using pacli-
taxel, docetaxel, and one recent phase II trial using com-
bination therapy of vinorelbine plus mitomycin were
cited for evaluating the transition probabilities of health
status along the model arms. Standard therapy consisted
of mitomycin plus vinblastine. Utility data and cost data
were collected from literature, data from previous iMTA
studies and the Dutch Pharmaceutical Compass. The
study was conducted from the hospital perspective and
only direct medical costs were taken into account. The
base year was 1998. RESULTS: Vinorelbine plus mito-
mycin has the lowest incremental cost-effectiveness ratio
of US$17114 per quality adjusted life year (QALY) (1
US$  2.3 NLG), followed by paclitaxel of US$ 30,270
per QALY, and docetaxel of US$49,739 per QALY. Fur-
thermore, vinorelbine plus mitomycin has the highest
QALY value of 0.43, compared to paclitaxel (0.35), doc-
etaxel (0.34) and mitomycin/vinblastin (0.29). Compared
to the standard therapy incremental cost-effectiveness of
vinorelbine/mitomycin is US$23,046 per QALY, which is
the lowest of all alternatives. CONCLUSION: Vinorel-
bine plus mitomycin is the most cost-effective second-line
chemotherapy for metastatic breast cancer patients com-
pared to paclitaxel, docetaxel and standard chemother-
apy with mitomycin/vinblastin.
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OBJECTIVES: To develop a clinical/economic decision
analysis model to estimate the costs, cost-effectiveness,
and usage probabilities of current treatments for early,
recurrent, and metastatic breast cancer in six countries
(U.S., U.K., Germany, Italy, France, Japan). METHODS:
Breast cancer treatment guidelines developed by a U.S.
oncology provider network (NCCN) were used as the ini-
tial basis for developing decision analysis-based treat-
ment pathways by disease stage. These guidelines were
modified to reflect current treatment patterns in each
country via a series of panel discussions with breast can-
cer thoughtleaders representing the six countries. The
multi-national treatment pathways were then validated
by six additional thought leader panels (one panel per
country, two to four participants per panel). For each
country, the probability distribution for every decision
node in the pathway was obtained from market research
or thought leader expert opinion. For each therapy, costs
were obtained from standardized databases, government
sources, published literature, and a provider survey for
the following categories: drug acquisition and adminis-
tration, monitoring, adverse event treatments, and hospi-
talization. RESULTS: Inputting the country-specific proba-
bility data into the multi-national pathway structure
generated 24 unique decision models (4 breast cancer
stages per country). In total, the model includes over 70
unique treatments for breast cancer and has approxi-
mately 144 million decision nodes when all treatment
combinations are considered. The model generates the
following outcomes for each country: rates of treatment
and treatment scenarios, cost per treatment, probable
cost per patient, and cost-effectiveness. The model also
examines the effect of varying cost and probability sce-
narios to reflect country-specific treatment practices and
international variations. CONCLUSIONS: When devel-
oping a comprehensive, multi-national model of an entire
disease, using clinical guidelines and thought leader input
as a basis can generate a valuable decision-making tool
used to examine the economic impact of existing and de-
velopment products as well as identifying cost-effective
treatment pathways.
